Evidence map›Paper›PMID 39050757›Full record

ArticleFrontiers in pharmacology2024

Advancing drug discovery through assay development: a survey of tool compounds within the human solute carrier superfamily.

Daniela Digles, Alvaro Ingles-Prieto, Vojtech Dvorak, Tamara A M Mocking, Ulrich Goldmann, Andrea Garofoli, Evert J Homan, Alberto Di Silvio, Lucia Azzollini, Francesca Sassone and 25 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Daniela Digles *Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
Alvaro Ingles-Prieto *CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Vojtech DvorakCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Tamara A M MockingDivision of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
Ulrich GoldmannCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Andrea GarofoliCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Evert J HomanScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Alberto Di SilvioAxxam SpA, Bresso, Italy.
Lucia AzzolliniAxxam SpA, Bresso, Italy.
Francesca SassoneAxxam SpA, Bresso, Italy.
Mario FogazzaAxxam SpA, Bresso, Italy.
Felix BärenzSanofi, Integrated Drug Discovery, Industriepark Hoechst, Frankfurt am Main, Hessen, Germany.
Antje PommereauSanofi, Integrated Drug Discovery, Industriepark Hoechst, Frankfurt am Main, Hessen, Germany.
Yasmin ZuschlagSanofi, Integrated Drug Discovery, Industriepark Hoechst, Frankfurt am Main, Hessen, Germany.
Jasper F OomsDivision of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
Jeppe Tranberg-JensenCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Jesper S HansenCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Josefina StankaLead Identification and Characterization, Bayer Pharmaceuticals, Wuppertal, Germany.
Hubert J SijbenDivision of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
Helena BatoulisLead Identification and Characterization, Bayer Pharmaceuticals, Wuppertal, Germany.
Eckhard BenderLead Identification and Characterization, Bayer Pharmaceuticals, Wuppertal, Germany.
Riccardo MartiniDepartment of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
Adriaan P IJzermanDivision of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
David B SauerCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Laura H HeitmanDivision of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
Vania ManolovaCSL Vifor, StGallen, Switzerland.
Juergen ReinhardtNovartis Pharma AG, Basel, Switzerland.
Alexander EhrmannLead Identification and Characterization, Bayer Pharmaceuticals, Wuppertal, Germany.
Philipp LeippeCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Gerhard F EckerDepartment of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
Kilian V M HuberCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Thomas LicherSanofi, Integrated Drug Discovery, Industriepark Hoechst, Frankfurt am Main, Hessen, Germany.
Lia ScarabottoloAxxam SpA, Bresso, Italy.
Tabea WiedmerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Giulio Superti-FurgaCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With over 450 genes, solute carriers (SLCs) constitute the largest transporter superfamily responsible for the uptake and efflux of nutrients, metabolites, and xenobiotics in human cells. SLCs are associated with a wide variety of human diseases, including cancer, diabetes, and metabolic and neurological disorders. They represent an important therapeutic target class that remains only partly exploited as therapeutics that target SLCs are scarce. Additionally, many small molecules reported in the literature to target SLCs are poorly characterized. Both features may be due to the difficulty of developing SLC transport assays that fulfill the quality criteria for high-throughput screening. Here, we report one of the main limitations hampering assay development within the RESOLUTE consortium: the lack of a resource providing high-quality information on SLC tool compounds. To address this, we provide a systematic annotation of tool compounds targeting SLCs. We first provide an overview on RESOLUTE assays. Next, we present a list of SLC-targeting compounds collected from the literature and public databases; we found that most data sources lacked specificity data. Finally, we report on experimental tests of 19 selected compounds against a panel of 13 SLCs from seven different families. Except for a few inhibitors, which were active on unrelated SLCs, the tested inhibitors demonstrated high selectivity for their reported targets. To make this knowledge easily accessible to the scientific community, we created an interactive dashboard displaying the collected data in the RESOLUTE web portal (https://re-solute.eu). We anticipate that our open-access resources on assays and compounds will support the development of future drug discovery campaigns for SLCs.

Indexed as

KNIMEsolute carriertool compoundtransport assaytransport protein

Identifiers

PMID39050757
PMCPMC11267547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.